Pathophysiology and clinical importance of hyperhomocysteinemia: clinical intervention studies.
Hyperhomocysteinemia is a cardiovascular disease risk factor in the general population and in patients with renal failure. This article summarizes the results of recent total homocysteine-lowering intervention studies in individuals without renal failure and in patients with renal failure. Although almost all of the published studies mainly focused on the total homocysteine-lowering effect and not on cardiovascular disease outcomes of folic acid and vitamin therapy, recent work has gained important insights into this area of developing concern.
Sunder-Plassmann
G
G
Universtitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse, Universität Wien, Austria. sunder@nephro.imed3.akh-wien.ac.at
Födinger
M
M
D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D005492:Folic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications / Q000188:drug therapy*; D051437:Renal Insufficiency / Q000150:complications / Q000628:therapy
D005492:Folic Acid